KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Enterprise Value: 2010-2025

Historic Enterprise Value for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $811.9 million.

  • Nektar Therapeutics' Enterprise Value rose 15739.45% to $811.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.2 million, marking a year-over-year increase of 118.66%. This contributed to the annual value of -$83.7 million for FY2024, which is 57.27% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Enterprise Value is $811.9 million, which was up 461.15% from $144.7 million recorded in Q2 2025.
  • Nektar Therapeutics' Enterprise Value's 5-year high stood at $2.6 billion during Q1 2021, with a 5-year trough of -$323.8 million in Q1 2023.
  • For the 3-year period, Nektar Therapeutics' Enterprise Value averaged around -$42.3 million, with its median value being -$92.1 million (2025).
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 586.65% in 2023, then spiked by 15,739.45% in 2025.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Enterprise Value stood at $1.8 billion in 2021, then slumped by 104.56% to -$80.2 million in 2022, then crashed by 144.18% to -$195.8 million in 2023, then skyrocketed by 57.27% to -$83.7 million in 2024, then soared by 15,739.45% to $811.9 million in 2025.
  • Its Enterprise Value stands at $811.9 million for Q3 2025, versus $144.7 million for Q2 2025 and -$92.1 million for Q1 2025.